
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer reported a strong performance in the fourth quarter of 2024, with revenues exceeding expectations, primarily driven by the sales of key products such as Comirnaty, Paxlovid, Eliquis, and Ibrance. The company maintains an optimistic outlook for fiscal year 2025, emphasizing stabilization in revenues from COVID-19 products while focusing on pipeline opportunities and cost realignment. Management's strategy includes leveraging insights from ongoing clinical updates and exploring business development opportunities, which positions Pfizer favorably for sustained growth in the pharmaceutical sector.
Bears say
The analysis indicates significant risks associated with Pfizer's key marketed products, including disappointing commercial execution and potential regulatory setbacks, which may undermine investor confidence in the company's growth prospects. Furthermore, adjustments to estimated costs of goods sold (COGS) and revenue forecasts for multiple products, including reductions for Padcev and Abrysvo, reflect a cautious future outlook amid ongoing challenges and impairments in sales projections. Lastly, heightened concerns regarding potential US drug pricing reform could adversely impact Pfizer's positioning in the large-cap biopharma sector, adding to the negative sentiment surrounding its stock.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares